Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Significant Growth in Short Interest

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 461,661 shares, a growth of 609.4% from the August 15th total of 65,075 shares. Approximately 65.3% of the company’s stock are short sold. Based on an average daily trading volume, of 5,622,745 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC bought a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent SEC filing. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Price Performance

NASDAQ AEMD opened at $1.56 on Friday. Aethlon Medical has a 1 year low of $1.55 and a 1 year high of $41.35. The firm has a market cap of $1.11 million, a price-to-earnings ratio of -0.04 and a beta of 1.40. The company has a fifty day moving average price of $2.83 and a 200-day moving average price of $7.53.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) EPS for the quarter, missing the consensus estimate of ($3.92) by ($0.10). On average, research analysts anticipate that Aethlon Medical will post -5.74 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $1.50 price target on shares of Aethlon Medical in a research report on Tuesday, August 18th. Wall Street Zen raised Aethlon Medical to a “sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $1.50.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical?stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life?threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.